460 Studies Now Enrolling
A Double-Blind, Placebo-conrolled, Parallel-group, Multicenter, Multiregional, One Year Study To Assess The Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of Clinical Remission with Endoscopic Response at 16 Weeks Followed by Clinical and Endoscopic Remission at 52 Weeks in Subjects with Active Moderate Crohn;s Disease
A study for patients with active moderate Crohn's Disease using study drug Rifaximin
| Sponsor: | Salix Pharmaceuticals |
| Enrolling: | Male and Female Patients |
| IRB Number: | AAAP3200 |
| U.S. Govt. ID: | NCT02240121 |
| Contact: | Dania Lauer: 212-304-7256 / dl2908@columbia.edu |
Additional Study Information:
The purpose of the study is to determine if the experimental use of an antibiotic called rifaximin for upto one year can improve the symptoms of Crohns disease (like abdominalpain and liquid/very soft stools), and if rifaximin can improve the inflammation in the intestines causedby Crohns disease. The study is trying to determine if rifaximin, unlike other medicines forCrohns disease, can do these things by having an effect on the bacteria in the intestines, and if it canreduce disease processes that are causing inflammation in the intestines.
This study is closed
